Lead Product(s): Enx108A
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim
Deal Size: $1,000.0 million Upfront Cash: $1,000.0 million
Deal Type: Partnership January 09, 2020
Acquisition of worldwide exclusive rights adds extensive anti-IL-11 platform to Boehringer Ingelheim pipeline portfolio.